Pregnancy Outcome In Women With Polycystic Ovary Syndrome Who Continue Metformin During First Trimester
Background:Polycystic ovary syndrome (PCOS) is a heterogenous disorder affecting 6-15% of women of reproductive age and it is considered as the most common cause of chronic anovulation and anovulatory infertility, diagnostic criteria have been proposed that generally center on the features of hyperandrogenismoligomenorrhea and polycystic ovarian morphology.The aim of this work was the effect of continue metformin in the 1st trimester in women with PCOS and its effect on pregnancy outcomes. Methods: This was a prospective interventional study (clinical study) that was conducted at Obstetrics and gynecologicy department of Zagazig University Hospitals in the period from March 2019 to March 2020. Included 44 pregnantPCO women, the selected patients were divided into 2 equal groups; group (I) included 22 pregnant women who continue metformin therapy during the first trimester with mean age 28.05 ± 2.44; and group (II) included 22 pregnant women with PCOs and discontinue metformin therapy during the first trimester with mean age 29.14 ± 2.09.Results: Women who continue metformin therapy during first trimester in group (I) were having significantly lower weight gain, lower incidence of gestational diabetes mellitus (GDM), Insulin therapy and spontaneous abortion and insignificantly lower incidence of pregnancy induced hypertension (PIH) in comparison with women who discontinue metformin in group (II). With p-value: 0.001, 0.004, 0.036, 0.008 and 0.549 respectively.Conclusions: Continuing of metformin therapy during 1st trimester pregnancy in women with PCOS was associated with good maternal outcomes including decrease incidence of spontaneous miscarriage, gestational DM.